PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 176 filers reported holding PUMA BIOTECHNOLOGY INC in Q2 2018. The put-call ratio across all filers is 0.99 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $295,897,000 | -23.6% | 42,211 | 0.0% | 0.00% | – |
| Q2 2021 | $387,497,000 | -4.3% | 42,211 | +1.3% | 0.00% | – |
| Q1 2021 | $404,926,000 | +14.3% | 41,659 | +20.6% | 0.00% | – |
| Q4 2020 | $354,359,000 | +20.5% | 34,538 | +18.5% | 0.00% | – |
| Q3 2020 | $294,163,000 | -3.3% | 29,154 | 0.0% | 0.00% | – |
| Q2 2020 | $304,077,000 | +11.2% | 29,154 | -10.0% | 0.00% | – |
| Q1 2020 | $273,490,000 | -5.7% | 32,404 | -2.2% | 0.00% | – |
| Q4 2019 | $289,906,000 | -12.6% | 33,132 | +7.5% | 0.00% | – |
| Q3 2019 | $331,788,000 | +1.7% | 30,821 | +20.1% | 0.00% | – |
| Q2 2019 | $326,087,000 | -51.7% | 25,656 | +47.3% | 0.00% | -100.0% |
| Q1 2019 | $675,645,000 | +223.6% | 17,418 | +69.7% | 0.00% | – |
| Q4 2018 | $208,811,000 | -69.6% | 10,261 | -31.6% | 0.00% | -100.0% |
| Q3 2018 | $687,521,000 | -39.6% | 14,995 | -22.1% | 0.00% | 0.0% |
| Q2 2018 | $1,138,992,000 | -19.6% | 19,256 | -7.5% | 0.00% | 0.0% |
| Q1 2018 | $1,415,984,000 | -22.1% | 20,808 | +13.1% | 0.00% | -50.0% |
| Q4 2017 | $1,818,841,000 | -8.3% | 18,400 | +11.1% | 0.00% | 0.0% |
| Q3 2017 | $1,983,420,000 | +46.9% | 16,563 | +7.2% | 0.00% | +100.0% |
| Q2 2017 | $1,350,157,000 | +386.5% | 15,448 | +107.0% | 0.00% | – |
| Q1 2017 | $277,549,000 | +121100.4% | 7,461 | 0.0% | 0.00% | – |
| Q4 2016 | $229,000 | -73.5% | 7,461 | -42.1% | 0.00% | -100.0% |
| Q3 2016 | $864,000 | +130.4% | 12,891 | +2.4% | 0.00% | – |
| Q2 2016 | $375,000 | +1.4% | 12,591 | 0.0% | 0.00% | – |
| Q1 2016 | $370,000 | -75.3% | 12,591 | -34.1% | 0.00% | -100.0% |
| Q4 2015 | $1,498,000 | -80.3% | 19,106 | -81.1% | 0.00% | -75.0% |
| Q3 2015 | $7,623,000 | -36.7% | 101,151 | -1.9% | 0.01% | -33.3% |
| Q2 2015 | $12,037,000 | -69.1% | 103,110 | -37.5% | 0.01% | -68.4% |
| Q1 2015 | $38,982,000 | +27.7% | 165,100 | +2.4% | 0.04% | +31.0% |
| Q4 2014 | $30,529,000 | -17.8% | 161,300 | +3.7% | 0.03% | -21.6% |
| Q3 2014 | $37,121,000 | +281.6% | 155,600 | +5.6% | 0.04% | +270.0% |
| Q2 2014 | $9,728,000 | – | 147,400 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HARVARD MANAGEMENT CO INC | 600,000 | $45,216,000 | 3.56% |
| Avalon Global Asset Management LLC | 32,900 | $2,479,000 | 1.79% |
| CORNERSTONE CAPITAL MANAGEMENT LLC | 495,145 | $37,314,000 | 1.58% |
| BB BIOTECH AG | 521,991 | $39,337,000 | 1.25% |
| WEATHERBIE CAPITAL, LLC | 137,041 | $10,327,000 | 1.20% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 5,686,668 | $428,527,000 | 1.19% |
| TOBAM | 318,384 | $23,994,000 | 0.94% |
| Orbimed Advisors | 1,195,500 | $90,093,000 | 0.91% |
| Capital International Sarl | 109,405 | $8,245,000 | 0.74% |
| CAPITAL INTERNATIONAL LTD /CA/ | 145,697 | $10,980,000 | 0.73% |